Related Experiment Video

Updated: Dec 28, 2025

Endobronchial Ultrasound-guided Intratumoral Injection of Cisplatin for the Treatment of Isolated Mediastinal Recurrence of Lung Cancer
04:04

Endobronchial Ultrasound-guided Intratumoral Injection of Cisplatin for the Treatment of Isolated Mediastinal Recurrence of Lung Cancer

Published on: February 12, 2017

10.8K

Three-year outcomes with brentuximab vedotin plus bendamustine as first salvage therapy in relapsed or refractory

Ann S LaCasce1, R Gregory Bociek2, Ahmed Sawas3

  • 1Dana-Farber Cancer Institute, Boston, MA, USA.

British Journal of Haematology
|February 13, 2020
PubMed
Abstract

No abstract available in PubMed .

Keywords:
Hodgkin lymphomaautologous stem cell transplantationbendamustinebrentuximab vedotinfirst salvage therapy

More Related Videos

Murine Model of Leukemia Relapse to Induction Chemotherapy for Acute Lymphoblastic Leukemia
08:31

Murine Model of Leukemia Relapse to Induction Chemotherapy for Acute Lymphoblastic Leukemia

Published on: October 17, 2025

485
Tumor Treating Field Therapy in Combination with Bevacizumab for the Treatment of Recurrent Glioblastoma
06:15

Tumor Treating Field Therapy in Combination with Bevacizumab for the Treatment of Recurrent Glioblastoma

Published on: October 27, 2014

27.7K

Related Experiment Videos

Last Updated: Dec 28, 2025

Endobronchial Ultrasound-guided Intratumoral Injection of Cisplatin for the Treatment of Isolated Mediastinal Recurrence of Lung Cancer
04:04

Endobronchial Ultrasound-guided Intratumoral Injection of Cisplatin for the Treatment of Isolated Mediastinal Recurrence of Lung Cancer

Published on: February 12, 2017

10.8K
Murine Model of Leukemia Relapse to Induction Chemotherapy for Acute Lymphoblastic Leukemia
08:31

Murine Model of Leukemia Relapse to Induction Chemotherapy for Acute Lymphoblastic Leukemia

Published on: October 17, 2025

485
Tumor Treating Field Therapy in Combination with Bevacizumab for the Treatment of Recurrent Glioblastoma
06:15

Tumor Treating Field Therapy in Combination with Bevacizumab for the Treatment of Recurrent Glioblastoma

Published on: October 27, 2014

27.7K

Related Concept Videos

Treatment Resistant Cancers02:56

Treatment Resistant Cancers

3.6K
Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...
3.6K

Articles linked to this work by shared authors, journal, and citation graph.

A multicenter phase II study of glofitamab plus polatuzumab-R-CHP for patients with diffuse large B-cell lymphoma.

Blood·2026

Teclistamab versus lenalidomide-dexamethasone in high-risk smoldering multiple myeloma: a randomized phase 2 trial.

Nature medicine·2026

MRD negativity by PBMCs and ctDNA confirms deep and durable responses after epcoritamab monotherapy in R/R FL.

Blood advances·2026

Real-world clinical outcomes in patients with CLL previously treated with covalent BTKi and BCL2i regimens.

Blood neoplasia·2026

Outcomes of patients with relapsed or refractory classic Hodgkin lymphoma after frontline brentuximab vedotin.

Blood cancer journal·2026

Treatment intensity, illness burden, and disparities in newly diagnosed diffuse large B-cell lymphoma treated at an urban academic center.

Leukemia & lymphoma·2026

Flow cytometric assessment of T-cell receptor β-chain constant region 1/2 skewing as a surrogate marker for clonality in human T-cell leukaemia virus type-1-infected cells.

British journal of haematology·2026

The leukaemia in pregnancy study, a national multicentre retrospective study of pregnancy outcomes in women with concurrent or historic diagnoses of acute leukaemia.

British journal of haematology·2026

Phase 3, randomised, placebo-controlled trial of voxelotor for the resolution of leg ulcers in sickle cell disease: RESOLVE.

British journal of haematology·2026

Repertoire diversity and dynamics of peripheral Th17 after allogeneic haematopoietic stem cell transplantation.

British journal of haematology·2026

Frailty and quality of life in a real-world multiple myeloma population.

British journal of haematology·2026

Rapid molecular screening of adult AML: Experience from the Spanish CETLAM cooperative group.

British journal of haematology·2026

Pharmacogenetics in HIV therapy: a review of key biomarkers, regulatory annotations, and clinical dosing guidelines.

Pharmacogenomics·2026

EXPRESS: A novel mouse model of cerebral venous sinus thrombosis based on photochemical-induction combined with in situ injection.

Journal of cerebral blood flow and metabolism : official journal of the International Society of Cerebral Blood Flow and Metabolism·2026

Ocular Gene Therapy in China: Technological Framework, Clinical Translation, and Future Perspectives.

Human gene therapy·2026

Targeting fibroimmune remodeling in androgenetic alopecia: emerging opportunities for RNA-based drug discovery.

Expert opinion on drug discovery·2026

[IDH-mutant gliomas. State of the art].

Zhurnal voprosy neirokhirurgii imeni N. N. Burdenko·2026

Amniotic Epithelial Stem Cells-Derived Exosomes Attenuate the Lesion of Alveolar Epithelial Cells Induced by SARS-CoV-2 Spike Protein via SENP3- Triggered FGF9 deSUMOylation.

Advanced biology·2026
See all related articles
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies
Jove
Visualize
Contact Us